tirzepatide versus semaglutide side effects Comparative safety and of and tirzepatide: Implications for clinical decision-making in obesity management Tirzepatide caused roughly half as

is now 7.2 mg per week as of March 2026, following FDA review of the STEP UP trial

The GSEA demonstrated a significant association between the identified prognostic signature and key pathways involved in immunity, metabolism, and cancer, including antigen processing and presentation, glutathione metabolism, pathways in cancer, and MAPK signaling pathway

However, as of March 2024, the FDA maintains that it can still be safely consumed

What matters is establishing early on whether a hereditary predisposition is also at play

Journal of Pediatric Endocrinology and Metabolism , 22(11), 10531061

There have also been reports of gallbladder disease, including cholelithiasis (gallstones) and cholecystitis, possibly related to rapid weight loss